SGLT2i in heart failure: can their benefits be expanded across the entire spectrum of ejection fraction?-Reference-Cited by-同舟云学术

SGLT2i in heart failure: can their benefits be expanded across the entire spectrum of ejection fraction?

Published:2022-10 Issue:10 Volume:75 Page:833-841
ISSN:1885-5857
Container-title:Revista Española de Cardiología (English Edition)
language:en
Short-container-title:Revista Española de Cardiología (English Edition)

Author:

Requena-Ibáñez Juan Antonio,Santos-Gallego Carlos G.,Badimón Juan José

Funder

Sociedad Española de Cardiología

Publisher

Elsevier BV

Subject

General Medicine

Reference49 articles.

1. Real world heart failure epidemiology and outcome: A population-based analysis of 88,195 patients;Farre;PLoS One.,2017

2. Heart Disease and Stroke Statistics-2021 Update: A Report From the American Heart Association;Virani;Circulation.,2021

3. Epidemiology and pathogenesis of heart failure with preserved ejection fraction;Nair;Rev Cardiovasc Med.,2020

4. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC);Ponikowski;Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail.,2016

5. Mid-range ejection fraction does not permit risk stratification among patients hospitalized for heart failure;Gomez-Otero;Rev Esp Cardiol.,2017

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. SGLT2i and loop diuretic withdrawal or downtitration in heart failure;Revista Española de Cardiología (English Edition);2023-11

2. Revista Española de Cardiología 2022;Revista Española de Cardiología;2023-05